嗜麦芽窄食单胞菌
鲍曼不动杆菌
重症监护医学
临床微生物学
医学
寡养单胞菌
铜绿假单胞菌
多重耐药
革兰氏阴性细菌感染
抗菌剂
传染病(医学专业)
抗生素耐药性
微生物学
抗药性
抗生素
生物
疾病
假单胞菌
内科学
细菌
遗传学
作者
Rafael Cantón,Patrícia Ruíz-Garbajosa
出处
期刊:Revista española de quimioterapia : publicación oficial de la Sociedad Española de Quimioterapia
[Sociedad Española de Quimioterapia]
日期:2023-11-24
卷期号:36 (Suppl1): 46-51
标识
DOI:10.37201/req/s01.11.2023
摘要
In recent years, new antimicrobials have been introduced in therapeutics, including new beta-lactam-beta-lactamase inhibitor combinations and cefiderocol in response to therapeutic needs in the face of increasing resistance. There are also different treatment guidelines for infections caused by these microorganisms that have been approved by different professional societies, including those of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Disease Society of America (IDSA) and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). All of them are based on scientific evidence, but with differences in the weight of expert opinion in their recommendations. Both ESCMID and IDSA include recommendations for the treatment of extended-spectrum beta-lactamase-producing microorganisms. The IDSA is the only one including AmpC producers, all address the treatment of infections caused by carbapenem-resistant Enterobacterales and Acinetobacter baumannii and multidrug-resistant or difficult-to-treat Pseudomonas aeruginosa, and the IDSA and SEIMC include recommendations on the treatment of Stenotrophomonas maltophilia. Future guidelines should integrate new antimicrobials and new innovative management options not covered by current guidelines.
科研通智能强力驱动
Strongly Powered by AbleSci AI